Legislative Affairs

“One of the penalties of not participating in politics is that you will be governed by your inferiors.”

Plato

The mission of APCI’s Legislative Affairs division is to promote and protect the political and economic interests of all APCI members. In order to accomplish that mission, Legislative Affairs:

  • Provides lobbyist and/or legislative assistance in all APCI member states
  • Identifies pharmacy-friendly political candidates and generate funding to support them
  • Contributes to state associations and organizations with similar legislative focus
  • Identifies political leaders to meet and key meetings or conferences to attend
  • Establishes routine and structured legislative meetings in each state
  • Leverages APCI account representatives and staff personnel
  • Utilizes APCI's Board of Directors to attend selected legislative events
  • Encourages APCI member participation and support of NCPA
  • Maintains a Washington, D.C., presence, supporting NCPA and developing direct relationships

For more information about APCI's Legistative Affairs division, contact us or call (800) 532-2724.

6

Jan

2017

Carter named to E&C commitee

Rep. Buddy Carter (R-Ga.) has been selected to serve on the influential House Energy and Commerce Committee.

27

Dec

2016

NCPA Advocacy Update 12.27.16

This week's update includes news on the DEA's revision to its registrant renewal policy, pharmacy group outreach to the president-elect, and more!

19

Dec

2016

NCPA Advocacy Update 12.19.16

This week's Advocacy Update includes information on changes to the DEA's registrant renewal process, resources for states regarding Medicaid reform, and much more!

5

Dec

2016

NCPA Advocacy Update 12.5.16

With the presidential transition in full swing and Congress back in session, there's lots to cover in this week's advocacy update!


21

Nov

2016

NCPA Advocacy Update 11.21.16

This week's update includes information on pharmacy champions getting leadership roles in Congress, a delay in Part D prescriber enrollment, and an updated "do not compound" list from the FDA.

First 55565758 Last